Table 3.
Change on clinical symptom measures between baseline and treatment week 12. ^
Olanzapine (N = 40) | Quetiapine (N = 31) | Risperidone (N = 33) | Placebo (N = 47) | |
---|---|---|---|---|
ADCS-ADL total score, mean change (SD) | −6.1 (8.2) * | −1.0 (7.7) | −1.1 (8.8) | 0.5 (8.4) |
ADAS-Cog total score, mean change (SD) | 0.7 (6.1) | 0.8 (6.9) | 1.7 (5.2) | 1.3 (5.7) |
MMSE score, mean change (SD) | −0.1 (3.7) | −0.8 (3.8) | −0.8 (3.2) | −0.7 (2.7) |
ADRQL total score, mean change (SD) | 6.4 (12.6) | 6.7 (11.7) | 2.1 (12.1) | 4.1 (15.8) |
Caregiver Activity Survey, mean change in hours (SD) | 0.2 (4.8) | −0.7 (4.3) | −1.1 (4.7) | −0.6 (4.1) |
Mean change score for those patients taking the assigned phase 1 medication at week 12 are shown.
For ADCS-ADL, MMSE, and ADRQL, a change score >0 reflects clinical improvement. For ADAS-Cog and Caregiver Activity Survey, a change score <0 reflects clinical improvement.
p<.001, pairwise comparison vs. placebo; ANCOVA model with adjustment for pooled site and baseline score.